Impact of Intestinal Microbiota on Uremic Toxins Productions

Not Applicable

Completed

• Conditions: CKD; Uremia
• Interventions: Other: Ex vivo exploration of the effect of a probiotic over precursor indole production

• Registration Number: NCT04768309
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Chronic renal failure (CKD) affects 3 million people in France and is characterized by the accumulation of uremic toxins (UTs) such as p-cresyl sulfate (PCS) and indoxyl sulfate (IS) which participate in cardiovascular complications and disturbance of the carbohydrate metabolism associated with CKD. These UTs are not eliminated by dialysis due to their high affinity for albumin and alternative strategies to dialysis must be developed to decrease the production of TUs in patients not yet in dialysis. The dysregulation of the intestinal microbiota observed during CKD increases the generation of UTs in the intestine, by the transformation of amino acids derived from proteins (such as tyrosine and tryptophan transformed respectively into PCS and, IS). Thus, modulation of the intestinal microbiota seems to be an attractive target for reducing the production of UTs and the comorbidities associated with CKD. Some studies have demonstrated the potential interest of probiotics in lowering the plasma concentration of UTs, but the effects remain unclear. In order to test the interest of probiotics during CKD, the investigators have, in collaboration with the Nestlé laboratory and the ProDigest platform, the possibility of testing probiotics using a human intestine simulator before the investigation of experimental and human models. For this the investigators would need a collection of fresh stools. The fresh stools will be instilled in artificial intestine to test the efficacy of selected probiotics on UTs production.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-02-12
• Study First Submitted QC: 2021-02-22
• Study First Posted: 2021-02-24
• Study Start: 2021-06-04
• Primary Completion: 2021-07-13
• Study Completion: 2021-07-13
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-26
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Age between 18 and 80 years old
• Non diabetic (fasting blood glucose <1.26 g / L, or lack of insulin or oral antidiabetic treatment)
• BMI between 18 and 30 kg / m²
• Patient with CKD stage 4-5 ( eDFG < 30 ml/min/1.73m2 CKD-EPI)
• Not dialyzed
• No history of kidney transplant
• Patient followed in the nephrology department of Pr FOUQUE at the Lyon Sud hospital center

Read More

Exclusion Criteria

• Active inflammatory, infectious, cardiovascular or neoplastic disease
• Colectomy, resection of the small intestine or cholecystectomy
• Patient having received antibiotics, prebiotics, probiotics in the last 3 months.
• Patient using laxatives (more than 2 doses per day for the last 3 months)
• Known renal pathology or known urologic malformation (healthy volunteer only)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CKD group	Ex vivo exploration of the effect of a probiotic over precursor indole production	CKD adult patients stage 4-5 Without diabetes BMI between 18 and 30 kg/m2
Healthy volunteers group	Ex vivo exploration of the effect of a probiotic over precursor indole production	Adult without chronic treatment, without renal dysfunction

Primary Outcome Measures

Name	Time	Method
Production of precursor of one of major uremic toxins: indole	Indoles production will be measured 48 hours after instillation of fresh feces in the artificial intestine	The main endpoint is the concentration of the precursor of indoxyl sulfate (indole) in the lumen of the artificial intestine with a microbiota of a patient with CKD compared to the concentration of indol in the lumen of artificial intestine with a microbiota from a patient with CKD and supplemented with a probiotic (supplied by Nestlé)

Secondary Outcome Measures

Name	Time	Method
Biochemical parameters	48 hours after instillation of fresh feces in the human intestine simulator	Volume of gas production in a human intestine simulator.
Intestinal microbiota composition	48 hours after instillation of fresh feces in the human intestine simulator	Study of the composition of the intestinal microbiota by 16s analysis
Uremic toxins production	48 hours after instillation of fresh feces in the human intestine simulator	Concentration of various uremic toxins in a human intestine simulator (p-cresyl sulfate, p-cresol, indole-3-acetic acid, etc.).
Intestinal permeability in a human intestine simulator	48 hours after instillation of fresh feces in the human intestine simulator	It will be measured by the electrical transepithelial resistance of the intestinal cells.
Production of short-chain fatty acids (SCFA)	48 hours after instillation of fresh feces in the human intestine simulator	Concentration of short-chain fatty acids (SCFA) (acetate, propionate, butyrate, isobutyrate, isovalerate and isocaproate) human intestine simulator

Trial Locations

Locations (1)

Lyon Sud University Hospital; 🇫🇷 Pierre-Bénite, Rhône, France